Press Releases May 1, 2026 08:05 AM

Bel Fuse Announces Upcoming Conference Schedule for May 2026

Bel Fuse Announces May 2026 Investor Conference Participation and Presentation Schedule

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn

Bel Fuse Inc., a Nasdaq-listed global provider of critical electronic components and solutions for aerospace, defense, industrial, and data-driven sectors, announced its schedule for investor conferences in May 2026. The company’s key executives will participate in three major industry conferences presenting its business outlook and engaging in investor meetings. Information and presentations will be accessible through the company's investor relations portal.

Bel Fuse Announces Upcoming Conference Schedule for May 2026
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Bel Fuse will participate in three major investor conferences in May 2026 including Oppenheimer, KeyBanc, and Craig-Hallum events.
  • Senior leadership including CEO Farouq Tuweiq and CFO Lynn Hutkin will lead the presentations and meetings.
  • Bel Fuse focuses on aerospace, defense, industrial, and data-driven markets providing critical electronic components and customized solutions.

WEST ORANGE, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Bel Fuse Inc. (Nasdaq: BELFA and BELFB), a global designer, manufacturer, and provider of critical electronic components, systems and solutions for customers in aerospace, defense, industrial, and data-driven markets, today announced its investor conference schedule for May 2026:

  • Oppenheimer 21st Annual Industrial Growth Conference
    Lynn Hutkin, CFO
    Mark Hodkinson, VP Finance & Corporate Controller
    Monday, May 4, 2026
    Conducting virtual meetings throughout the day with a virtual presentation at 12:00 PM ET
  • KeyBanc Industrials & Basic Materials Conference
    Farouq Tuweiq, CEO
    Lynn Hutkin, CFO
    Wednesday, May 27, 2026
    InterContinental, Boston
    Conducting meetings throughout the day
  • Craig-Hallum 23rd Annual Institutional Investor Conference
    Farouq Tuweiq, CEO
    Lynn Hutkin, CFO
    Thursday, May 28, 2026
    Depot Renaissance Hotel, Minneapolis
    Conducting meetings throughout the day

The investor presentation deck and webcast will be accessible via the investor relations section of the webcast at: https://ir.belfuse.com/events-and-presentations.

About Bel
Bel (www.belfuse.com) designs, manufactures, and markets critical electronic components, systems and solutions for customers in aerospace, defense, industrial, and data-driven markets. Understanding that our customers face increasingly complex technical challenges, Bel delivers a comprehensive portfolio of solutions including power systems, high-reliability connectors and cable assemblies, circuit protection, and networking products that enable Original Equipment Manufacturers (OEMs) to bring their innovations to market. Bel partners closely with customers to deliver both customized and standard solutions tailored to their specific applications and performance requirements. With manufacturing facilities and technical support teams worldwide, Bel serves as a strategic partner to customers who require proven reliability in demanding end markets.

Contacts:
Bel Fuse Inc.
Lynn Hutkin, CFO
ir@belf.com

Three Part Advisors
Jean Marie Young, Managing Director
Steven Hooser, Partner
jyoung@threepa.com
shooser@threepa.com


Risks

  • Market reception of the conference presentations may not meet investor expectations leading to stock volatility.
  • Dependence on cyclical and defense-related industries exposes Bel Fuse to sector-specific risks like government budget changes and industrial downturns.
  • Global supply chain or technical challenges could impact product delivery and customer relationships impacting financial performance.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026